Bookmark and Share
BioAssay: AID 504740

Inhibitors of Bloom's syndrome helicase: Mouse Plasma Stability Profiling

Survival of cells and the faithful propagation of the genome depend on elaborate mechanisms of detecting and repairing DNA damage. Treatment of advanced cancer relies on radiation therapy or chemotherapy, which kill cancer cells by causing extensive DNA damage. It is often found, that cancer cells develop resistance to therapy through enhanced activity of DNA repair functions; this has led to an more ..
_
   
 Tested Compounds
 Tested Compounds
All(1)
 
 
Active(1)
 
 
 Tested Substances
 Tested Substances
All(1)
 
 
Active(1)
 
 
 Related BioAssays
 Related BioAssays
AID: 504740
Data Source: NCGC (BLMA606)
Depositor Category: NIH Molecular Libraries Probe Production Network
Deposit Date: 2011-05-09
Hold-until Date: 2012-05-06
Modify Date: 2012-05-08

Data Table ( Complete ):           View Active Data    View All Data
BioActive Compound: 1
Related Experiments
Show more
AIDNameTypeComment
2386Probe Development Summary for Inhibitors of Bloom's syndrome helicase (BLM)Summarydepositor-specified cross reference: Summary AID
2364qHTS Validation Assay for Inhibitors of Bloom's syndrome helicase (BLM)Confirmatorysame project related to Summary assay
2528qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)Confirmatorysame project related to Summary assay
2585qHTS Confirmation Assay for Inhibitors of Bloom's syndrome helicase (BLM)Confirmatorysame project related to Summary assay
2712Counterscreen for BLMA Inhibitors: ADP Fluorescence Polarization Displacement AssayConfirmatorysame project related to Summary assay
504662Inhibitors of BLM Helicase: DNA Unwinding Measured by Gel Electrophoresis - BLM Helicase ActivityConfirmatorysame project related to Summary assay
504663Inhibitors of BLM Helicase: DNA Unwinding Measured by Gel Electrophoresis - RecQL1 Helicase CounterscreenConfirmatorysame project related to Summary assay
504736Inhibitors of Bloom's syndrome helicase: Efflux Ratio Profiling AssayOthersame project related to Summary assay
504737Inhibitors of Bloom's syndrome helicase: Caco-2 Permeability Profiling AssayOthersame project related to Summary assay
504738Inhibitors of Bloom's syndrome helicase: Aqueous Profiling AssayOthersame project related to Summary assay
504739Inhibitors of Bloom's syndrome helicase: Metabolic Stability ProfilingOthersame project related to Summary assay
504741Inhibitors of Bloom's syndrome helicase: PBS Stability Profiling AssayOthersame project related to Summary assay
720549qHTS for Inhibitors of Bloom's syndrome helicase (BLM): Helicase ATPase Orthogonal Confirmatory Assay for SAROthersame project related to Summary assay
720550qHTS for Inhibitors of Bloom's syndrome helicase (BLM): Thiazole Orange DNA Binding Counterscreen for SAR.Othersame project related to Summary assay
720555qHTS for Inhibitors of Bloom's syndrome helicase (BLM): Helicase DNA unwinding fluorescent orthogonal confirmatory assay for SAROthersame project related to Summary assay
Description:
Survival of cells and the faithful propagation of the genome depend on elaborate mechanisms of detecting and repairing DNA damage. Treatment of advanced cancer relies on radiation therapy or chemotherapy, which kill cancer cells by causing extensive DNA damage. It is often found, that cancer cells develop resistance to therapy through enhanced activity of DNA repair functions; this has led to an increased interest in developing drugs that interfere with DNA repair, which could sensitize cancer cells to conventional therapy. Bloom syndrome helicase (BLM), is important in resolving abnormal DNA structures formed during replication or homologous recombination. Shutting down the expression of BLM leads to chromosomal instability and higher radiation sensitivity in cultured cells. After the completion of a qHTS campaign, secondary assays, and rounds of medicinal chemistry, a compound was identified to be further characterized through in vitro ADME assays.

The stability of the lead compound in mouse plasma is tested because this parameter has a significant impact on many ADME-concerned properties of drugs, such as uptake, distribution, transport, and bioavailability.

NIH Chemical Genomics Center [NCGC]
NIH Molecular Libraries Probe Production Centers Network [MLPCN]

MLSCN Grant: MH087284
PI Name: Dr. Opher Gileadi, Structural Genomics Consortium, University of Oxford, UK
Protocol
2uM of compound is incubated in mouse plasma; the reference compound is procaine. Compounds are incubated at 37 deg C for the pre-determined time periods and the when aliquots are removed. Samples are analyzed with LC-MS/MS.
Comment
Compounds are "active" if percent remaining after 48 h is equal or more than 90%; "inactive" if percent remaining after 48 h is less than 90%.
PUBCHEM_ACTIVITY_SCORE is the closets whole number of percent remaining after 48 hours.
Result Definitions
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1Percent RemainingPercent remaining after 48 h incubation in mouse plasma##Float%
2Compound QCSource of compound QCString
Additional Information
Grant Number: MH087284

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
PageFrom: